Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pressure Ulcers - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pressure Ulcers - Pipeline Review, H1 2017, provides an overview of the Pressure Ulcers (Dermatology) pipeline landscape. Pressure ulcers are an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pressure Ulcers - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pressure Ulcers (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Pressure Ulcers (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pressure Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 3 and 5 respectively. Pressure Ulcers (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Pressure Ulcers (Dermatology). - The pipeline guide reviews pipeline therapeutics for Pressure Ulcers (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Pressure Ulcers (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Pressure Ulcers (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Pressure Ulcers (Dermatology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Pressure Ulcers (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Pressure Ulcers (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Pressure Ulcers - Overview Pressure Ulcers - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Pressure Ulcers - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Pressure Ulcers - Companies Involved in Therapeutics Development EyeGene Inc Izun Pharmaceuticals Corp MediWound Ltd NovaLead Pharma Pvt Ltd RegeneRx Biopharmaceuticals Inc RMB-Research GmbH Pressure Ulcers - Drug Profiles AG-100 - Drug Profile Product Description Mechanism Of Action R&D Progress EG-Decorin - Drug Profile Product Description Mechanism Of Action R&D Progress EscharEx - Drug Profile Product Description Mechanism Of Action R&D Progress IZN-6D4 - Drug Profile Product Description Mechanism Of Action R&D Progress NLP-328 - Drug Profile Product Description Mechanism Of Action R&D Progress RGN-137 - Drug Profile Product Description Mechanism Of Action R&D Progress Statmicoll - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Pressure Ulcers - Drug Profile Product Description Mechanism Of Action R&D Progress Pressure Ulcers - Dormant Projects Pressure Ulcers - Discontinued Products Pressure Ulcers - Product Development Milestones Featured News & Press Releases Aug 24, 2016: MediWound's EscharEx to be Featured at International Society for Burn Injuries 2016 Dec 04, 2015: RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment Jan 09, 2009: RegeneRx Reports Phase II Pressure Ulcer Trial Results Sep 22, 2008: RegeneRx/Sigma-Tau Completes Patient Enrollment Of Second Phase II Clinical Trial With RGN-137 Aug 20, 2008: RegeneRx Completes Patient Enrollment Of First Phase II Clinical Trial Nov 02, 2004: RegeneRx Gets Cleared To Initiate Phase II Clinical Trial With T�4 For Chronic Pressure Ulcers Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Pressure Ulcers, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pressure Ulcers - Pipeline by EyeGene Inc, H1 2017 Pressure Ulcers - Pipeline by Izun Pharmaceuticals Corp, H1 2017 Pressure Ulcers - Pipeline by MediWound Ltd, H1 2017 Pressure Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017 Pressure Ulcers - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017 Pressure Ulcers - Pipeline by RMB-Research GmbH, H1 2017 Pressure Ulcers - Dormant Projects, H1 2017 Pressure Ulcers - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.